Antiretroviral therapy is used to suppress the HIV in People Living with HIV AIDS (PLWHA). This improves the life quality and prevents AIDS’s mortality. Manokwari, Fak-Fak and Sorong had high HIV AIDS cases in West Papua. The study’s aim was to overview the antiretroviral therapy by identifiying the adherence, clinical, and immunological condition of PLWHA in these 3 sites during August to October 2019. This was a cross sectional study. Respondents were 221 PLWHA, who receiving antiretroviral therapy for at least 6 months, male and female aged ≥15 years old. Data collections were through interviews, medical records, measurement and laboratory examinations. The data were processed statistically univariate and bivariate. Majority of respondents from all sites were 15-45 years old, women, married, senior high school-university graduated, employee, Papuan, no tuberculosis, stage 3-4 of HIV at beginning of therapy, normal Body Mass Index (BMI), CD4 + cell ≥350 cells/mm.³ The proportion of respondents with adherence ≥95% in Manokwari and Sorong were higher than in Fak-Fak, but the adherence in all sites were still not optimal yet. Most of respondents had good clinical and immunological conditions. There were relationship between tuberculosis, BMI, stage of HIV at beginning of therapy, and adherence to CD4 + counts after therapy. Keywords: antiretroviral, HIV/AIDS, adherence, clinical condition, CD4 + , West Papua Abstrak Terapi antiretroviral digunakan untuk menekan HIV pada Orang dengan HIV/AIDS (ODHA) karena mampu meningkatkan kualitas hidup dan mencegah kematian karena AIDS. Manokwari, Fak-Fak dan Kota Sorong memiliki kasus HIV AIDS tinggi di Papua Barat. Penelitian ini bertujuan menggambarkan terapi antiretroviral dengan mengidentifikasi kepatuhan pengobatan, kondisi klinis, dan imunologis ODHA di 3 lokasi tersebut pada Agustus sampai Oktober 2019. Desain penelitian adalah potong lintang. Responden sebanyak 221 ODHA dengan kriteria sedang terapi minimal 6 bulan, laki-laki dan perempuan berusia di atas 15 tahun. Data penelitian dikumpulkan dari wawancara, rekam medis, pengukuran dan pemeriksaan laboratorium. Data diolah univariat dan bivariat secara statistik. Hasil analisis menunjukkan mayoritas responden dari semua lokasi penelitian berusia 15-45 tahun, perempuan, menikah, pendidikan SLTA-Pendidikan Tinggi, bekerja, asli Papua, tidak ada tuberkulosis, sakit HIV stadium 3 dan 4 di awal terapi, Indeks Massa Tubuh normal, memiliki CD4 + ≥350 sel/mm³. Proporsi responden dengan tingkat kepatuhan ≥95% di Manokwari dan Sorong lebih tinggi dibandingkan di Fak-Fak, namun kepatuhan terapi di Manokwari, Fak-Fak, dan Kota Sorong masih belum optimal. Kondisi klinis serta imunologis sebagian besar responden relatif baik. Ada hubungan antara sakit TB, Indeks Massa Tubuh, stadium sakit HIV di awal terapi, dan kepatuhan dengan jumlah CD4 + setelah terapi. Kata kunci: antiretroviral, HIV/AIDS, kepatuhan, kondisi klinis, CD4 + , Papua Barat.

Background : Antiretroviral (ARV) therapy is one of the efforts to combat HIV/AIDS in Indonesia, especially West Papua. One of the side effects using ARV is impaired liver function in People Living with HIV/AIDS (PLWHA). ARV therapy evaluation to liver disorders can be seen from the Serum Glutamic Oxaloacetic Transaminase (SGOT)/ Serum Glutamic Pyruvic Transaminase (SGPT) level.Objective : To find out the effect of ARV Fixed Dosed Combination (FDC) to liver function of PLWHA patients in West Papua.Methods : A cross-sectional study, involving 110 respondents who were PLWHA patients receiving ARV at Voluntary Counselling and Testing (VCT) service of hospital in Manokwari, Sorong, and Fak-fak. Laboratory tests was used to examine the liver function. Other variable data were obtained from medical records. The Fisher Exact Test with a significance level of <0.05 was used to determine the effect of ARV to liver function.Results : Respondents had no liver problems with normal SGOT and SGPT values, i.e. 72,7% and 76.4%, respectively. While, the rest had mild and moderate toxicity. Respondent experiencing moderate toxicity was 2 patients who regularly took FDC in Sorong.Conclussion : The FDC using in ARV therapy did not significantly influence the increase of SGOT and SGPT on PLWHA patients in West Papua.

Hightlight:Clinical conditions, CD4+ cell counts, and the viral copies number in the blood for AIDS/HIV were given antiretroviral therapy.The profile of CD4+ levels and plasma viral load in HIV patients receiving antiretroviral therapyThe lower CD4+ cell counts and higher viral loads happen in HIV-infected’s men. Abstract:Highly active antiretroviral therapy (HAART) is expected to reduce human immunodeficiency virus (HIV) morbidity and mortality. Antiretroviral therapy in HIV patients is given based on clinical conditions, CD4+ cell counts, and the number of viral copies in the blood. This study aimed to determine the profile of CD4+ levels and plasma viral load in HIV patients receiving antiretroviral therapy. This was a cross-sectional study conducted within six months at Voluntary Counseling and Testing (VCT) in Jayawijaya Hospital, Papua, Indonesia. The CD4+ levels were measured using CD4+ counter and viral plasma was checked using Polymerase Chain Reaction (PCR) for 90 patients. The results showed more female patients had a CD4+ level <200 cells/mm3, a higher number of copies of the virus in the blood plasma, and stages of disease 3 and 4. Statistically, there was a significant relationship between CD4+ levels and gender with a p-value = 0.00. HIV-infected males were more likely to have lower CD4+ cell counts and higher viral loads than females.

Background<br />The body mass index (BMI) may contribute somewhat to drug metabolism, thus affecting the efficacy of antiretroviral therapy (ART). CD4+ counts   in people infected with HIV are essential in determining the stage of the disease, initiation of antiretroviral therapy, opportunistic infections and evaluating treatment outcomes. The aim of this study was to determine the association of BMI and clinical stage with CD4+ counts in HIV patients seeking treatment using first-line antiretroviral therapy (ART).<br /><br />Methods<br />An analytic study with a cross-sectional approach was conducted involving 251 HIV/AIDS patients who had received first-line antiretrovirals over six months. BMI, clinical staging according to WHO and CD4 + were collected. Multiple linear regression was used to evaluate the relationship between BMI, clinical stage and CD4+.<br /><br />Results<br />Among the enrolled patients, the median age was 36 years, 135 (55%) of the patients was female, 102 (40.6%) was overweight/obese, 161 (64.1%) was in stage 3 of the disease, and the median CD4+ count was 389 cells/mm3. Multiple linear regression test showed two variables with a significant effect on CD4+ count, namely BMI (B=69.247; 95 % CI : 42.886-95.608) and clinical stage (B=61.590; 28.910-94.270). BMI was the most influencing factor for CD4+ count (β=0.307) compared to clinical stage (β=0.216). <br /><br />Conclusions<br />Body mass index was the most influencing factor for CD4 + counts of HIV/AIDS patients. Regular ART can increase CD4+ counts and maintain the health of HIV/AIDS patients.